Targeted Therapies for Melanoma

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2020 Sep 9

PMID 32899184

Citations 6

Authors

Karel Smetana Jr

Lukas Lacina

Ondrej Kodet

Affiliations

Soon will be listed here.

Abstract

The incidence of cutaneous malignant melanoma (CMM) is significantly increasing worldwide.[...].

Citing Articles

Alantolactone enhances the sensitivity of melanoma to MAPK pathway inhibitors by targeting inhibition of STAT3 activation and down-regulating stem cell markers.

Zhao K, Zhao Q, Dai X, Wen X, Luo X, Duan Y Cancer Cell Int. 2024; 24(1):191.

PMID: 38822350 PMC: 11143683. DOI: 10.1186/s12935-024-03371-9.

Recent advances in nanomaterial-based drug delivery systems for melanoma therapy.

Parhi R, Kaishap P, Jena G ADMET DMPK. 2024; 12(1):107-150.

PMID: 38560710 PMC: 10974823. DOI: 10.5599/admet.2088.

Autoimmunity, cancer and COVID-19 abnormally activate wound healing pathways: critical role of inflammation.

Gal P, Brabek J, Holub M, Jakubek M, Sedo A, Lacina L Histochem Cell Biol. 2022; 158(5):415-434.

PMID: 35867145 PMC: 9305064. DOI: 10.1007/s00418-022-02140-x.

Exosomes produced by melanoma cells significantly influence the biological properties of normal and cancer-associated fibroblasts.

Strnadova K, Pfeiferova L, Prikryl P, Dvorankova B, Vlcak E, Frydlova J Histochem Cell Biol. 2021; 157(2):153-172.

PMID: 34837514 PMC: 8847298. DOI: 10.1007/s00418-021-02052-2.

The Human Melanoma Proteome Atlas-Complementing the melanoma transcriptome.

Betancourt L, Gil J, Sanchez A, Doma V, Kuras M, Murillo J Clin Transl Med. 2021; 11(7):e451.

PMID: 34323402 PMC: 8299047. DOI: 10.1002/ctm2.451.

References

Diazzi S, Tartare-Deckert S, Deckert M . Bad Neighborhood: Fibrotic Stroma as a New Player in Melanoma Resistance to Targeted Therapies. Cancers (Basel). 2020; 12(6). PMC: 7352197. DOI: 10.3390/cancers12061364. View

Becco P, Gallo S, Poletto S, Frascione M, Crotto L, Zaccagna A . Melanoma Brain Metastases in the Era of Target Therapies: An Overview. Cancers (Basel). 2020; 12(6). PMC: 7352598. DOI: 10.3390/cancers12061640. View

Brustugun O, Moller B, Helland A . Years of life lost as a measure of cancer burden on a national level. Br J Cancer. 2014; 111(5):1014-20. PMC: 4150272. DOI: 10.1038/bjc.2014.364. View

Palusova V, Renzova T, Verlande A, Vaclova T, Medkova M, Cetlova L . Dual Targeting of BRAF and mTOR Signaling in Melanoma Cells with Pyridinyl Imidazole Compounds. Cancers (Basel). 2020; 12(6). PMC: 7352453. DOI: 10.3390/cancers12061516. View

Ruggiero C, Malpicci D, Fattore L, Madonna G, Vanella V, Mallardo D . ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine Neuregulin. Cancers (Basel). 2019; 11(10). PMC: 6826737. DOI: 10.3390/cancers11101425. View

Huynh S, Mortier L, Dutriaux C, Maubec E, Boileau M, Dereure O . Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study. Cancers (Basel). 2020; 12(6). PMC: 7352575. DOI: 10.3390/cancers12061666. View

Hellmund P, Schmitt J, Roessler M, Meier F, Schoffer O . Targeted and Checkpoint Inhibitor Therapy of Metastatic Malignant Melanoma in Germany, 2000-2016. Cancers (Basel). 2020; 12(9). PMC: 7565277. DOI: 10.3390/cancers12092354. View

Balakirouchenane D, Guegan S, Csajka C, Jouinot A, Heidelberger V, Puszkiel A . Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma. Cancers (Basel). 2020; 12(4). PMC: 7226106. DOI: 10.3390/cancers12040931. View

Penas C, Apraiz A, Munoa I, Arroyo-Berdugo Y, Rasero J, Ezkurra P . RKIP Regulates Differentiation-Related Features in Melanocytic Cells. Cancers (Basel). 2020; 12(6). PMC: 7352799. DOI: 10.3390/cancers12061451. View

10.

Krayem M, Aftimos P, Najem A, van den Hooven T, van den Berg A, Hovestad-Bijl L . Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance. Cancers (Basel). 2020; 12(2). PMC: 7072684. DOI: 10.3390/cancers12020512. View

11.

Del Bianco P, Stagni C, Giunco S, Fabozzi A, Elefanti L, Pellegrini S . TERT Promoter Mutations Differently Correlate with the Clinical Outcome of MAPK Inhibitor-Treated Melanoma Patients. Cancers (Basel). 2020; 12(4). PMC: 7226422. DOI: 10.3390/cancers12040946. View

12.

Tetu P, Delyon J, Andre J, Reger De Moura C, Sabbah M, Ghanem G . FGF2 Induces Resistance to Nilotinib through MAPK Pathway Activation in KIT Mutated Melanoma. Cancers (Basel). 2020; 12(5). PMC: 7281633. DOI: 10.3390/cancers12051062. View

13.

Lebbe C, Dutriaux C, Lesimple T, Kruit W, Kerger J, Thomas L . Pimasertib Versus Dacarbazine in Patients With Unresectable -Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover. Cancers (Basel). 2020; 12(7). PMC: 7408351. DOI: 10.3390/cancers12071727. View

14.

Greco A, Safi D, Swami U, Ginader T, Milhem M, Zakharia Y . Efficacy and Adverse Events in Metastatic Melanoma Patients Treated with Combination BRAF Plus MEK Inhibitors Versus BRAF Inhibitors: A Systematic Review. Cancers (Basel). 2019; 11(12). PMC: 6966686. DOI: 10.3390/cancers11121950. View

15.

Kodet O, Kucera J, Strnadova K, Dvorankova B, Stork J, Lacina L . Cutaneous melanoma dissemination is dependent on the malignant cell properties and factors of intercellular crosstalk in the cancer microenvironment (Review). Int J Oncol. 2020; 57(3):619-630. PMC: 7384852. DOI: 10.3892/ijo.2020.5090. View